ClinicaliQ Trial Snapshot
- A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis — Recruiting • Phase II • Dermatology • NCT07277660.
- Trial testing different doses of galvokimig versus placebo in adults with moderate-to-severe eczema to find the most effective safe dose.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD). Conditions: Atopic Dermatitis Interventions: Galvokimig, Placebo Lead Sponsor: UCB Biopharma SRL Planned Enrollment: 160 participants